Cibus (CBUS) Stock Overview
An agricultural biotechnology company that develops and licenses gene-edited plant traits. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CBUS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cibus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$4.19 |
| 52 Week Low | US$1.09 |
| Beta | 1.66 |
| 1 Month Change | -8.61% |
| 3 Month Change | -31.00% |
| 1 Year Change | -43.21% |
| 3 Year Change | -91.27% |
| 5 Year Change | -99.39% |
| Change since IPO | -99.75% |
Recent News & Updates
CBUS: Higher Future P/E And Raised Discount Rate Will Shape Rerating Potential
Analysts have raised their price target on Cibus by $1.10. They cite updated assumptions around discount rate, revenue growth and profit margin as key reasons for the change.CBUS: Higher Future P/E Expectations Will Drive Rerated Upside Potential
Narrative Update on Cibus The analyst price target for Cibus has been raised by $1.10. Analysts point to an updated fair value estimate of $3.00, a higher discount rate, adjusted revenue growth and profit margin assumptions, and a much higher future P/E outlook as key drivers of the change.Recent updates
CBUS: Higher Future P/E And Raised Discount Rate Will Shape Rerating Potential
Analysts have raised their price target on Cibus by $1.10. They cite updated assumptions around discount rate, revenue growth and profit margin as key reasons for the change.CBUS: Higher Future P/E Expectations Will Drive Rerated Upside Potential
Narrative Update on Cibus The analyst price target for Cibus has been raised by $1.10. Analysts point to an updated fair value estimate of $3.00, a higher discount rate, adjusted revenue growth and profit margin assumptions, and a much higher future P/E outlook as key drivers of the change.CBUS: Premium Price And Dilutive Equity Raise Will Limit Future Upside
Analysts have revised their price target on Cibus to $1.90, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E, while keeping fair value steady at $1.90 as they balance growth expectations with valuation similar to recent Neutral views seen in Community Financial research. Analyst Commentary Recent street research on other financial names shows a pattern of cautious stances where valuation and growth expectations are tightly linked.CBUS: Premium Share Price And Equity Issuance Will Restrain Future Returns
The analyst price target for Cibus has been revised to $65 from $72 as analysts recalibrate expected profit margins and apply a higher assumed future P/E multiple, while keeping their fair value estimate broadly unchanged and highlighting valuation as the key constraint on further upside. Analyst Commentary Recent Street research on Cibus highlights a cautious tone, with several bearish analysts pointing to valuation as the main sticking point.CBUS: Equity Offering And Execution Demands Will Constrain Future Share Returns
Analysts have adjusted their price target on Cibus to $1.90, reflecting updated assumptions around the discount rate, long term revenue growth, and future P/E, while keeping their fair value view unchanged at $1.90. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cibus, even as the fair value view sits at $1.90.CBUS: Reset Fair Value And Equity Raise Will Restrain Long Term Upside
Analysts have reset their fair value estimate for Cibus to $1.90 from $15.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. Analyst Commentary Bearish analysts have reset their expectations for Cibus, and the sharp cut in the fair value estimate to US$1.90 signals a more cautious stance on the stock.CBUS: Latin American Rice Trait Partnership Will Shape Long Term Upside
Narrative update Analysts have raised their fair value estimate for Cibus from US$1.60 to US$15.00, citing updated assumptions for revenue growth, profit margins and future P/E expectations as key drivers of the change. Analyst Commentary While the updated fair value estimate for Cibus now stands at US$15.00, some readers may find it useful to consider how bearish analysts have approached similar valuation resets in other names.
Licensing And EU Harmonization Will Open New Markets
Following sharp reductions in both Cibus’s future P/E ratio and discount rate, reflecting improved earnings outlook and lower perceived risk, the consensus analyst price target has dropped from $16.38 to $14.40. What's in the News Cibus was dropped from multiple Russell indices, including the Russell 2000, 2500, 3000, Small Cap Completeness Index, and their respective value subsets.
Licensing And EU Harmonization Will Open New Markets
Transitioning to a commercial trait company and leveraging licensing agreements can unlock new revenue streams and enhance market penetration.Cibus: Expanding Opportunities And Growing Accessible Market
Summary Cibus, a gene editing pioneer in agriculture, has announced collaborations that could significantly increase its revenues. The company has partnered with Interoc to breed rice hybrids with herbicide tolerance for the Latin American market. Further deals in Latin America could double or triple accessible rice acreage. Cibus has also achieved a breakthrough in regenerating wheat plants from single cells, opening up a large addressable market for enhanced forms of wheat. Read the full article on Seeking AlphaShareholder Returns
| CBUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.4% | 0.1% | 2.6% |
| 1Y | -43.2% | 35.5% | 26.2% |
Return vs Industry: CBUS underperformed the US Biotechs industry which returned 42% over the past year.
Return vs Market: CBUS underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CBUS volatility | |
|---|---|
| CBUS Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CBUS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CBUS's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 118 | Peter Beetham | www.cibus.com |
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.
Cibus, Inc. Fundamentals Summary
| CBUS fundamental statistics | |
|---|---|
| Market cap | US$109.85m |
| Earnings (TTM) | -US$127.08m |
| Revenue (TTM) | US$3.64m |
Is CBUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBUS income statement (TTM) | |
|---|---|
| Revenue | US$3.64m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.64m |
| Other Expenses | US$130.72m |
| Earnings | -US$127.08m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 14, 2026
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,492.31% |
| Debt/Equity Ratio | 1,078.6% |
How did CBUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 07:53 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cibus, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Donald McLee | Berenberg |
| Kenneth Zaslow | BMO Capital Markets Equity Research |